ORIC Pharma restructures, cuts 20% workforce, and extends cash runway to 2H 2028

Oric Pharmaceuticals, Inc.

Initiated strategic pipeline prioritization, eliminating discovery research and reducing workforce by ~20%; expects ~$1.9M one-time charge in Q3 2025.
Proforma cash and investments of $436.4M as of June 30, 2025, extending cash runway to 2H 2028 (previously 2H 2027).
Q2 2025 R&D expenses $30.5M (up from $28.9M), G&A expenses $8.5M (up from $7.1M); no revenue reported.
ORIC-944 Phase 1b data showed 59% PSA50 and 24% PSA90 responses; enozertinib (formerly ORIC-114) continues enrollment in NSCLC trials.

item 2.02item 9.01item 2.05

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.